August 4th Week, 2025 Regulatory Events 🎯 Health Canada issued a NOC/c for Iovance Biotherapeutics, Inc.'s lifileucel (autologous TIL therapy) for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy including an anti-PD-1, and if BRAF V600 mutant, BRAF inhibitor ± MEK inhibitor, and who have no satisfactory alternative treatment options. (Ref 1) ❓ How is this approval going to impact the Melanoma treat

July 2nd Week, 2025 Regulatory Updates 🎯 The EC approved BeOne Medicines' tislelizumab (anti-PD-1) + gemcitabine + cisplatin for the first-line Tx of metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. (Ref 1) ❓ What are the other key Asia-specific trials emerging in this indication? 🎯 The UK’s MHRA granted marketing authorization to ImmunityBio, Inc.'s nogapendekin alfa inbakicept-pmln (lymphocyte-stimulating agent

June 1st Week, 2025 Regulatory Events 🎯 Takeda and Pfizer’s brentuximab vedotin (Adcetris; CD30 ADC) + ECADD chemo regimen has been approved by the European commission for the Tx of adult patients with newly diagnosed stage IIb with risk factors/III/IV Hodgkin lymphoma. (Ref 1) ❓ Can brentuximab-based regimen be the standard of care? What are its strengths and limitations? 🎯 Tempest Therapeutics’ amezalpat (selective PPAR⍺ antagonist) has been granted an Orphan Drug Desi